Crossmark Global Holdings Inc. acquired a new position in shares of Opko Health Inc. (NASDAQ:OPK) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 17,216 shares of the biotechnology company’s stock, valued at approximately $118,000.

Other large investors have also modified their holdings of the company. State Board of Administration of Florida Retirement System increased its position in shares of Opko Health by 7.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after purchasing an additional 27,940 shares during the last quarter. Intrinsic Edge Capital Management LLC acquired a new stake in shares of Opko Health during the 2nd quarter worth about $658,000. Balyasny Asset Management LLC increased its position in shares of Opko Health by 78.7% during the 2nd quarter. Balyasny Asset Management LLC now owns 40,262 shares of the biotechnology company’s stock worth $265,000 after purchasing an additional 17,728 shares during the last quarter. ETF Managers Group LLC acquired a new stake in shares of Opko Health during the 2nd quarter worth about $702,000. Finally, First Manhattan Co. increased its position in shares of Opko Health by 31.4% during the 3rd quarter. First Manhattan Co. now owns 98,550 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 23,550 shares during the last quarter. 22.91% of the stock is owned by hedge funds and other institutional investors.

OPK has been the subject of a number of research analyst reports. Jefferies Group restated a “hold” rating and set a $6.50 target price (down from $6.80) on shares of Opko Health in a report on Thursday, August 10th. Zacks Investment Research cut Opko Health from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Cantor Fitzgerald initiated coverage on Opko Health in a report on Thursday, August 17th. They set an “overweight” rating and a $20.00 target price for the company. J P Morgan Chase & Co cut Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $12.00 to $7.00 in a report on Thursday, September 14th. Finally, BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Opko Health currently has an average rating of “Hold” and a consensus price target of $13.97.

In other Opko Health news, CEO Phillip Md Et Al Frost bought 80,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was purchased at an average price of $6.01 per share, for a total transaction of $480,800.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,444,395.51. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Opko Health, Inc. bought 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were acquired at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The disclosure for this purchase can be found here. Insiders bought a total of 1,052,238 shares of company stock valued at $4,374,796 in the last quarter. Company insiders own 40.19% of the company’s stock.

Opko Health Inc. (NASDAQ:OPK) opened at $5.04 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a 52 week low of $4.50 and a 52 week high of $12.15.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.03) EPS. equities analysts predict that Opko Health Inc. will post -0.27 EPS for the current fiscal year.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/crossmark-global-holdings-inc-takes-position-in-opko-health-inc-opk/1746897.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.